United Therapeutics Inc. stock gained on Monday after it shared positive news regarding its drug ralinepag, which achieved a significant milestone in clinical trials.

The stock’s movement comes as broader markets experienced declines, with the Nasdaq down 1.40% on the previous trading day.

Lung/Heart Disease Data

The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint, demonstrating a 55% reduction in the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH).

PAH is characterized by high blood pressure in the lung arteries, caused by narrowing and remodeling of the vessels, which forces the right heart to work harder, leading to heart failure.

Additionally, the study showed that ralinepag increased the odds of clinical improvement by 47% in predominantly pre-treated patients, with the company planning to submit a New Drug Application (NDA) to the FDA by the second half of 2026.

In the study, ralinepag was well-tolerated, and no new safety signals were observed, reinforcing its potential as a transformative treatment for PAH.

The results are expected to be presented at an upcoming international conference, further highlighting the drug’s promising efficacy and safety profile.

The broader market experienced declines on the previous trading day, with the Dow Jones down 1.04% and the S&P 500 falling 1.07%.

This backdrop of market weakness indicates that United Therapeutics’ gains are driven by company-specific news rather than overall market trends.

Technical Analysis

Currently, the stock is trading 8.5% below its 20-day simple moving average (SMA) and 5.2% below its 100-day SMA, suggesting some short-term weakness.

Over the past 12 months, shares have increased significantly and are positioned closer to their 52-week highs than lows, indicating a strong long-term trend.

The RSI is at 50.00, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating some bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should keep an eye on potential shifts in market sentiment.

Key Resistance: $537.50

Key Support: $480.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $491.00. Recent analyst moves include:

HC Wainwright & Co.: Buy (Raises Target to $600.00) (Feb. 26)

TD Cowen: Buy (Raises Target to $575.00) (Feb. 26)

Oppenheimer: Outperform (Raises Target to $600.00) (Feb. 26)

UTHR Price Action: United Therapeutics ( UTHR ) shares were up 3.98% at $503.90 at the time of publication on Monday, according to Benzinga Pro data.